200 related articles for article (PubMed ID: 15890924)
1. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
Barassi C; Soprana E; Pastori C; Longhi R; Buratti E; Lillo F; Marenzi C; Lazzarin A; Siccardi AG; Lopalco L
J Virol; 2005 Jun; 79(11):6848-58. PubMed ID: 15890924
[TBL] [Abstract][Full Text] [Related]
2. A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies.
Barassi C; Marenzi C; Pastori C; Longhi R; Lazzarin A; Lopalco L
New Microbiol; 2004 Apr; 27(2 Suppl 1):85-94. PubMed ID: 15646069
[TBL] [Abstract][Full Text] [Related]
3. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.
Bomsel M; Pastori C; Tudor D; Alberti C; Garcia S; Ferrari D; Lazzarin A; Lopalco L
AIDS; 2007 Jan; 21(1):13-22. PubMed ID: 17148963
[TBL] [Abstract][Full Text] [Related]
4. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge.
Zuber B; Hinkula J; Vödrös D; Lundholm P; Nilsson C; Mörner A; Levi M; Benthin R; Wahren B
Virology; 2000 Dec; 278(2):400-11. PubMed ID: 11118363
[TBL] [Abstract][Full Text] [Related]
5. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
Khurana S; Kennedy M; King LR; Golding H
J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
[TBL] [Abstract][Full Text] [Related]
6. Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.
Pastori C; Diomede L; Venuti A; Fisher G; Jarvik J; Bomsel M; Sanvito F; Lopalco L
J Virol; 2014 Apr; 88(7):3623-35. PubMed ID: 24403594
[TBL] [Abstract][Full Text] [Related]
7. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
8. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
9. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
[TBL] [Abstract][Full Text] [Related]
10. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.
Lopalco L; Barassi C; Pastori C; Longhi R; Burastero SE; Tambussi G; Mazzotta F; Lazzarin A; Clerici M; Siccardi AG
J Immunol; 2000 Mar; 164(6):3426-33. PubMed ID: 10706739
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
[TBL] [Abstract][Full Text] [Related]
12. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells.
Meng G; Wei X; Wu X; Sellers MT; Decker JM; Moldoveanu Z; Orenstein JM; Graham MF; Kappes JC; Mestecky J; Shaw GM; Smith PD
Nat Med; 2002 Feb; 8(2):150-6. PubMed ID: 11821899
[TBL] [Abstract][Full Text] [Related]
13. Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
Zaunders JJ; Kaufmann GR; Cunningham PH; Smith D; Grey P; Suzuki K; Carr A; Goh LE; Cooper DA
J Infect Dis; 2001 Mar; 183(5):736-43. PubMed ID: 11181150
[TBL] [Abstract][Full Text] [Related]
14. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
[TBL] [Abstract][Full Text] [Related]
15. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
[TBL] [Abstract][Full Text] [Related]
16. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes.
Patterson BK; Czerniewski M; Andersson J; Sullivan Y; Su F; Jiyamapa D; Burki Z; Landay A
Clin Immunol; 1999 Jun; 91(3):254-62. PubMed ID: 10370370
[TBL] [Abstract][Full Text] [Related]
18. High level expression, purification and characterization of recombinant CCR5 as a vaccine candidate against HIV.
Wu K; Xue X; Li M; Qin X; Zhang C; Li W; Hao Q; Wang Z; Liu Q; Zhang W; Zhang Y
Protein Expr Purif; 2013 Jun; 89(2):124-30. PubMed ID: 23542826
[TBL] [Abstract][Full Text] [Related]
19. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
20. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
Nakayama D; Misumi S; Mukai R; Tachibana K; Umeda M; Shibata H; Takamune N; Shoji S
J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
